• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, August 27, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

JMC|Insilico Medicine nominates novel AI-driven PHD inhibitor targeting anemia

Bioengineer by Bioengineer
January 19, 2024
in Chemistry
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Clinical stage generative artificial intelligence (AI)-driven biotechnology company InSilico Medicine (“InSilico”), today announced that the Journal of Medicinal Chemistry, an ACS Publications journal focusing on critical studies about molecular structure and biological activity, has published the company’s discovery of a novel PHD inhibitor for the treatment of anemia. The academic breakthrough is powered by Chemistry42, its proprietary generative chemistry platform consisting of more than 40 selected generative models.

Discovery of Novel and Potent Prolyl Hydroxylase Domain- Containing Protein (PHD) Inhibitors for The Treatment of Anemia

Credit: Journal of Medicinal Chemistry

Clinical stage generative artificial intelligence (AI)-driven biotechnology company InSilico Medicine (“InSilico”), today announced that the Journal of Medicinal Chemistry, an ACS Publications journal focusing on critical studies about molecular structure and biological activity, has published the company’s discovery of a novel PHD inhibitor for the treatment of anemia. The academic breakthrough is powered by Chemistry42, its proprietary generative chemistry platform consisting of more than 40 selected generative models.

 

As suggested in previous studies, the inhibition of prolyl hydroxylase domain enzymes (PHD) influences fundamental biological processes, including red blood cell production by regulating the Nobel prize-winning HIF-α pathway, thus indicating potential for the treatment of CKD-induced anemia.

 

Guided by a structure-based drug discovery (SBDD) strategy, Insilico’s scientists gathered structure information on the PHD target and known molecules, and generated series of molecule candidates with the help of Chemistry42. Utilizing built-in filters covering drug-likeness, pharmacophore clues, synthesis evaluation and more, the AI-generated candidates were ranked and prioritized before a hit compound was produced for further optimization.

 

“Thanks to Chemistry42, we had end-to-end assistance from molecule generation to hit compound selection,” said Xiaoyu Ding, the computational chemist sharing first authorship. “With the power of generative artificial intelligence, we could accelerate the drug discovery process without compromises in novelty or quality.”

 

Afterward, several rounds of synthesis test optimization yielded lead compound 15, which demonstrated a favorable in vitro/in vivo ADMET profile, a clean safety profile, and promising PK properties in multiple species. Moreover, the compound was proven to alleviate anemia in a rat disease model, with relatively simple synthesis steps.

 

“Given that more than 10% of the global population suffers from CKD, Insilico’s novel molecule could be a meaningful for further investigations and patients worldwide,” said Jianyu Xu, the medicinal chemist who co-authored the paper. “After comprehensive research into PHD inhibitors already available on the market, we hope to develop a novel noncarboxylic acid molecule for better permeability and PK profiles.”

 

About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.co



Journal

Journal of Medicinal Chemistry

DOI

10.1021/acs.jmedchem.3c01932

Article Title

Discovery of Novel and Potent Prolyl Hydroxylase Domain- Containing Protein (PHD) Inhibitors for The Treatment of Anemia

Article Publication Date

8-Jan-2024

Share12Tweet8Share2ShareShareShare2

Related Posts

Why Beer Foam Stays So Stable: The Science Behind the Perfect Pour

Why Beer Foam Stays So Stable: The Science Behind the Perfect Pour

August 26, 2025
SwRI Scientist Heads Science Team for New NASA Heliophysics AI Foundation Model

SwRI Scientist Heads Science Team for New NASA Heliophysics AI Foundation Model

August 26, 2025

Expanding Azole Chemistry with Precise N-Alkylation

August 26, 2025

Advancing Green Technology with More Efficient and Reliable SiC Devices

August 26, 2025

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    148 shares
    Share 59 Tweet 37
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    115 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

New Study Highlights Positive Impact of Diet and Exercise on Alcohol-Induced Liver Damage

CytoSorb® Enhanced Hemadsorption in Cardiac Surgery Outcomes

Amino Acids Drive Metabolic Dysfunction in Pulmonary Fibrosis

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.